UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brexit will affect UK’s supply of radioisotopes

BMJ (Online), 2018-03, p.k1020

Rooney, Claire M

2018

Volltextzugriff (PDF)

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13), p.2587-2593

2015

Volltextzugriff (PDF)

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

Cancer research (Chicago, Ill.), 2019-04, Vol.79 (7), p.1480-1492

2019

Volltextzugriff (PDF)

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8), p.2045-2056

2012

Volltextzugriff (PDF)

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Cancer discovery, 2016-08, Vol.6 (8), p.838-851

2016

Volltextzugriff (PDF)

Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate

Neurology, 2016-11, Vol.87 (18), p.1943-1953

2016

Volltextzugriff (PDF)

STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap

Nature communications, 2018-05, Vol.9 (1), p.2124-15, Article 2124

2018

Volltextzugriff (PDF)

The Epithelial Cell and Lung Cancer: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer

Respiration, 2011-01, Vol.81 (2), p.89-104

2011

Volltextzugriff (PDF)

Advances in Molecular Biology of Lung Disease

Chest, 2015-10, Vol.148 (4), p.1063-1072

2015

Volltextzugriff (PDF)

The Rac activator STEF (Tiam2) regulates cell migration by microtubule-mediated focal adhesion disassembly

EMBO reports, 2010-04, Vol.11 (4), p.292-298

2010

Volltextzugriff (PDF)

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

PloS one, 2016-02, Vol.11 (2), p.e0149628-e0149628

2016

Volltextzugriff (PDF)

Src-Induced Disassembly of Adherens Junctions Requires Localized Phosphorylation and Degradation of the Rac Activator Tiam1

Molecular cell, 2009-03, Vol.33 (5), p.639-653

2009

Volltextzugriff (PDF)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ breast cancer, 2023-08, Vol.9 (1), p.64-64, Article 64

2023

Volltextzugriff (PDF)

Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma

Frontiers in toxicology, 2023-06, Vol.5, p.1200650-1200650

2023

Volltextzugriff (PDF)

Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer

Chest, 2015-10, Vol.148 (4), p.1063-1072

2015

Volltextzugriff (PDF)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ breast cancer, 2023-09, Vol.9 (1), p.76-76, Article 76

2023

Volltextzugriff (PDF)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ breast cancer, 2023-08, Vol.9 (1), p.69-69, Article 69

2023

Volltextzugriff (PDF)

Biomarkers for precision medicine in airways disease

Annals of the New York Academy of Sciences, 2015-06, Vol.1346 (1), p.18-32

2015

Volltextzugriff (PDF)

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Clinical cancer research, 2017-09, Vol.23 (18), p.5366-5373

2017

Volltextzugriff (PDF)

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Journal of clinical oncology, 2021-01, Vol.39 (3), p.190-201

2021

Volltextzugriff (PDF)

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS287-TPS287

2023

Volltextzugriff (PDF)

The pathogenesis of mesothelioma is driven by a dysregulated translatome

Nature communications, 2021-08, Vol.12 (1), p.4920-17, Article 4920

2021

Volltextzugriff (PDF)

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

British journal of cancer, 2024-05, Vol.130 (8), p.1377-1387

2024

Volltextzugriff (PDF)

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS178-TPS178

2021

Volltextzugriff (PDF)

Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.108-108

2022

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(137)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(165)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Brexit will affect UK’s supply of radioisotopes

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate

STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap

The Epithelial Cell and Lung Cancer: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer

Advances in Molecular Biology of Lung Disease

The Rac activator STEF (Tiam2) regulates cell migration by microtubule-mediated focal adhesion disassembly

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

Src-Induced Disassembly of Adherens Junctions Requires Localized Phosphorylation and Degradation of the Rac Activator Tiam1

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma

Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Biomarkers for precision medicine in airways disease

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer

The pathogenesis of mesothelioma is driven by a dysregulated translatome

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281)

Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC)

Suchergebnisse filtern